FDA authorizes second COVID antiviral tablet, Merck’s molnupiravir, if no alternatives available


The Food and Drug Administration announced Thursday it had approved molnupiravir, a drug produced by Merck and Ridgeback Biotherapeutics, to deal with some American adults with COVID-19 who’re susceptible to extreme illness when no different choices are available. The tablets are supposed to be began inside 5 days of creating the primary signs. 

“Molnupiravir is limited to situations where other FDA-authorized treatments for COVID-19 are inaccessible or are not clinically appropriate and will be a useful treatment option for some patients with COVID-19 at high risk of hospitalization or death,” stated the FDA’s Dr. Patrizia Cavazzoni. 

The company’s transfer marks the second emergency authorization for an antiviral tablet to deal with COVID-19 in as many days, after the FDA greenlighted Pfizer’s Paxlovid on Wednesday. 

It comes forward of a feared surge that might overwhelm hospitals because the Omicron variant quickly spreads, with docs going through a scarcity of efficient medication to deal with Omicron circumstances this winter. Cavazzoni stated that the FDA believes each antiviral tablets will work in opposition to Omicron.

Molnupiravir’s authorization comes near a month after the FDA’s exterior advisers had wrestled with the tablet’s extra dangers and smaller efficacy in a slender vote

Merck and Ridgeback initially said an interim evaluation of their trial confirmed antiviral might minimize the danger of hospitalization or loss of life by 50% in comparison with placebo. The drugmakers’ final analysis confirmed a smaller relative threat discount of 30%. 

For Paxlovid, Pfizer has touted an efficacy of 89% amongst high-risk adults with COVID-19, and says their tablet doesn’t carry the identical theoretical dangers as Merck’s drug of driving worrying mutations or probably damaging the DNA of recipients. 

The two drugs work in another way. Paxlovid works by making an attempt to dam the flexibility of the virus to make copies of itself within the physique. Molnupiravir tries to drive a random cascade of errors within the replication course of, aiming to stunt its unfold. 

FDA officers acknowledged the priority voiced by a few of their advisers final month that molnupiravir may result in the unfold of an “escape mutant.” However, they stated the “hypothetical risk” could be mitigated by instructions for individuals to isolate whereas taking molnupiravir, which in trials dramatically decreased the quantity of virus within the physique over the 5 day course of remedy. 

The company’s advisers weren’t requested to weigh in on the tablet from Pfizer, which introduced remaining trial outcomes last week.

“We felt that we needed to proceed expeditiously with the authorization and we did not have pressing scientific questions that would benefit from advisory committee discussion,” the FDA’s Dr. John Farley told reporters on Thursday. 

In its authorization of the Merck tablet, the FDA stated it will ban youngsters from taking the drug over issues it might have an effect on the event of bones and cartilage. Women are additionally discouraged from taking the drug if they’re pregnant, and are beneficial to take steps to keep away from changing into pregnant whereas receiving molnupiravir.

“I think that, if an alternative agent comes along with better efficacy and fewer safety concerns, that this EUA should be immediately reconsidered,” stated Dr. Richard Murphy, a Veterans Affairs doctor on the committee final month.

However, White House officers say some 3 million programs of molnupiravir will probably be available by the top of subsequent month from Merck and Ridgeback Biotherapeutics — in comparison with solely 265,000 anticipated to be shipped by Pfizer of Paxlovid subsequent month.

Less than 65,000 programs will probably be available of Paxlovid beginning the primary week of January, the U.S. Department of Health and Human Services disclosed Wednesday. 

“According to Pfizer, the complex chemistry involved in creating the active ingredient in the pill means production takes about six to eight months.  So, supply of this product will ramp up over the next several months,” Jeffrey Zients, the White House’s high COVID-19 official, told reporters on Wednesday.

Merck’s remedy will arrive forward of a feared wave over the following month of hospitalizations and deaths brought on by the fast-spreading Omicron variant, which has rendered most available monoclonal antibody medication ineffective. 

Federal officers announced Thursday they’d halt distribution of monoclonal antibody medication from Eli Lilly and Regeneron, after the Centers for Disease Control and Prevention estimated Omicron had develop into the predominant variant nationwide. 

Jurisdictions and suppliers are at present rationing out an “extremely limited” provide of sotrovimab, the antibody drug from GlaxoSmithKline and Vir Biotechnology

Though some research now recommend Omicron might result in a smaller threat of hospitalization, scientists and well being authorities warn that the variant might nonetheless be extreme sufficient to inflict an enormous toll given its speedy unfold. 

“Regardless of where the relative severity of Omicron falls, the sheer number of cases projected means that even a relatively mild severity of the Omicron variant will severely stress, if not overwhelm, already strained health care systems across the country,” a consortium of illness forecasters stated in a joint statement on Wednesday.

A panel of specialists convened by the National Institutes of Health is predicted to subject tips quickly on the way to triage restricted provides of the 2 antiviral tablets, in addition to the monoclonal antibody therapies and remdesivir, an antiviral that’s administered intravenously.

The group previously recommended rationing restricted provides of monoclonal antibodies amongst excessive threat sufferers for treating those that are unvaccinated or in any other case unprotected by the vaccines, like those that are immunocompromised. 

“We’ve asked the NIH Guidelines Committee to put together a recommendation of when someone comes in with an acute infection and is in a risk group, which is what you want this to be for since we have a limited supply, that we would have a prioritization of what the best approach would be,” Dr. Anthony Fauci, the president’s chief medical adviser, told reporters on Wednesday.

Alexander Tin

CBS News reporter protecting public well being and the pandemic.


Please enter your comment!
Please enter your name here